Clinical and cost-effectiveness of diverse post-hospitalisation pathways for COVID-19: A UK evaluation utilising the PHOSP-COVID cohort - the PHOSP-COVID Study Collaborative Group; Briggs, AH; Ibbetson, A; Walters, A; Houchen-Wolloff, L; Armstrong, N; Emerson, T; Gill, R; Hastie, C; Little, P; Overton, C; Pimm, J; et al. (medRxiv, 2024)
Background Long Covid has emerged as a complex health condition for millions of people worldwide following the COVID-19 pandemic. Previously, we have categorised healthcare pathways for patients after discharge from hospital with COVID-19 across 45 UK sites. The aim of this work was to estimate the clinical and cost-effectiveness of these pathways.Methods We examined prospectively collected data from 1,013 patients at 12-months post-discharge on whether they felt fully recovered (self-report), number of newly diagnosed conditions (NDC), quality of life (EQ-5D-5L utility score compared to pre-covid estimate) and healthcare resource costs (healthcare records). An analysis of the cost-effectiveness was performed by combining the healthcare resource cost and one-year EQ5D (giving a quality adjusted life-year: QALY) using statistical models that accounted for observed confounding.Results At 1 year, 29% of participants felt fully recovered and 41% of patients had an NDC. The most comprehensive services, where all patients could potentially access assessment, rehabilitation, and mental health services, were more clinically effective when compared with either no service or light touch services (mean (SE) QALY 0.789 (0.012) vs 0.725 (0.026)), with an estimated cost per QALY of £1,700 (95% uncertainty interval: dominated to £24,800).Conclusion Our analysis supports the need for proactive, stratified, comprehensive follow-up for adults after hospitalisation with COVID-19 showing these services are likely to be both clinically and cost-effective according to commonly accepted thresholds.Competing Interest StatementAdditional conflicts of interest outside the funding for the project reported by the authors are: AB received funding from the NIHR and additional consultancy fees from Roche and Merck. AI received funding from the NIHR and European Research Council. NA and TE received funding from the NIHR only. SS received funding from the NIHR and further grants from the NIHR Programme Grant, the Wellcome Doctoral Training Programme, the HTA Project Grant, NIHR DHSC/UK Research and Innovation (UKRI) Covid-19 Rapid Response Initiative, NIHR Global Research Group, Actegy Limited, and NIHR Senior Investigator. They have also participated on boards for the National Institute of Clinical Excellence Expert of Adviser Panel - Long Covid, Wales Long Covid Advisory Board (expired), and NHS-E Long Covid Your Covid Recovery Working Group (expired). Additionally, SS have held the following roles: ATS Pulmonary Rehabilitation Assembly Chair (expired), Clinical Lead RCP Pulmonary Rehabilitation Accreditation Scheme (expired), and Clinical Lead NACAP Audit for Pulmonary Rehabilitation. AS received joint funding from the UKRI and NIHR. ABD received a personal Wellcome Career Development Fellowship. JQ has received grants from the Medical Research Council (MRC), NIHR, Health Data Research, GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Insmed, and Sanofi. JQ has also received additional consultancy fees from GlaxoSmithKline, Chiesi, and AstraZeneca. JDC has received grants from Astrazeneca, Boehringer Ingelheim, Grifols, Gileadsciences, Insmed, Genentech, and GlaxoSmithKline. Additionally, they have received consultancy fees from Astrazeneca, Boehringer Ingelheim, Grifols, Gileadsciences, Insmed, Genentech, GlaxoSmithKline, Antabio, Zambon, and Trudell. JDC also holds the following leadership roles; Chief Editor of the European Respiratory Journal, Chair of the British Thoracic Society Science and Research Committee, and Trustee of the British Thoracic Society. BR received support from the BHF Oxford CRE Transition. LVW received funding from the UKRI, NIHR, GlaxoSmithKline, and Asthma + Lung UK. Further grants for LVW were received from Orion Pharma, GlaxoSmithKline, Genetech, and AstraZeneca. LVW also received consultancy fees from Galapogos, Boehringer Ingelheim, with support for attending meetings from Genetech. Additionally, LVW participated in on a board for Galapagos and is an Associate Editor for the European Respiratory Journal. CEB received funding from the UKRI and NIHR. Grants and consultancy fees were received by CEB from 4D Pharma, Areteia, AstraZeneca, Chiesi, Genentech, GlaxoSmithKline, Mologic, Novartis, Regeneron Pharmaceuticals, Roche, and Sanofi. MM received funding from the NIHR. RAE received funding from the UKRI, MRC, and NIHR, further grants were received from the Wolfson Foundation, Genetech, and Roche. Consultancy fees were received by RAE from AstraZeneca and Evidera, speaker fees were received from Boeringher and Moderna, with support received from Chesi for attendance at meetings. RAE is the ERS Group 01.02 Pulmonary Rehabilitation and Chronic Care Chair and the ATS Pulmonary Rehabilitation Assembly Chair.Funding StatementThis work (PHOSP-HSR) is funded by the NIHR Policy Research Programme (NIHR202708). The parent PHOSP-COVID project is independent research jointly funded by the National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI) [PHOSP-COVID Post-hospitalisation COVID-19 study: a national consortium to understand and improve long-term health outcomes, grant references: MR/V027859/1 and COV0319].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of National Institute of Health Research gave ethical approval for this work. Reference: 20/YH/0225.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe PHOSP-COVID study website (https://www.phosp.org) contains an overview of the study, resources, information about people involved, and publications. Research activity using the study is organised across a series of Working Groups (Figure 3). These were established at the outset of the study to coordinate research, minimise duplication of efforts, and facilitate communication across research and clinical specialties. Researchers interested in undertaking research using PHOSP-COVID are encouraged to contact the relevant Working Group leads (https://www.phosp.org/working-group/) in the first instance. The data are currently held in the Outbreak Data Analysis Platform (ODAP, https://odap.ac.uk/). Researchers seeking to access these data are directed to https://www.phosp.org/resource/ for information and forms. Correspondence to be directed to Dr Rachael A Evans, the Co-Principal Investigator of PHOSP-COVID study phospatleicester.ac.uk. https://www.phosp.org/working-group/